Media stories about Threshold Pharmaceuticals (NASDAQ:MTEM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Threshold Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.8732049401769 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Threshold Pharmaceuticals (MTEM) traded down $0.05 during trading hours on Tuesday, hitting $8.05. 77,600 shares of the stock were exchanged, compared to its average volume of 95,474. Threshold Pharmaceuticals has a one year low of $3.85 and a one year high of $11.88.

A number of equities analysts have recently commented on the stock. Ladenburg Thalmann Financial Services assumed coverage on shares of Threshold Pharmaceuticals in a report on Thursday, August 3rd. They set a “buy” rating and a $10.00 price objective for the company. ValuEngine downgraded shares of Threshold Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Stifel Nicolaus reaffirmed a “hold” rating and set a $0.40 price objective on shares of Threshold Pharmaceuticals in a report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, September 14th.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-threshold-pharmaceuticals-mtem-stock-price/1703127.html.

Threshold Pharmaceuticals Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Insider Buying and Selling by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.